Antimicrobial Resistance WHO Report 2024: Global Burden, 2030 Targets & Action Plan

Antimicrobial resistance (AMR) is among the most consequential global health threats of the 21st century — a slow-moving pandemic that undermines the foundation of modern medicine. When bacteria, viruses, fungi, and parasites evolve to resist the drugs designed to kill them, common infections become untreatable, routine surgeries become dangerous, and the medical advances of the past century begin to unravel. The WHO’s latest report to the World Health Assembly presents the most comprehensive assessment yet of the global AMR burden, 2030 reduction targets, and the strategic framework needed to mount an effective response. This guide synthesizes the key findings and their implications for health systems, policymakers, and the broader public.

The Scale of the Antimicrobial Resistance Crisis

The numbers are stark. According to the Global Burden of Disease 2021 AMR analysis published in The Lancet, an estimated 4.71 million deaths were associated with bacterial antimicrobial resistance globally in 2021, with 1.14 million deaths directly attributable to bacterial AMR. To put this in perspective, AMR-associated mortality exceeds deaths from HIV/AIDS, malaria, or tuberculosis individually — yet receives a fraction of the global health investment and public attention.

The burden falls disproportionately on low- and middle-income countries, where access to quality healthcare, diagnostic capacity, and clean water and sanitation infrastructure is most limited. Sub-Saharan Africa and South Asia bear the highest per-capita AMR mortality, driven by a toxic combination of high infection rates, limited access to quality antibiotics, poor sanitation, and inadequate diagnostic capacity to identify resistant organisms and guide treatment decisions.

AMR is not a future threat — it is a current emergency. Every year that passes without adequate intervention sees resistance rates climb for critical pathogens, narrowing the treatment options available to clinicians worldwide. The economic burden compounds the health toll: AMR-related healthcare costs, lost productivity, and premature death represent an escalating drag on national economies and health systems. For those tracking innovations in healthcare, the AMR challenge represents one of the most urgent domains for technological and systemic intervention.

WHO 2030 Targets for Antimicrobial Resistance

The 2024 United Nations high-level meeting on AMR (September 26, 2024, New York) produced a political declaration adopted by the UN General Assembly that establishes concrete, measurable targets for the first time. These targets, to be achieved by 2030, provide a framework for global accountability:

• 10% mortality reduction: Reduce global deaths associated with bacterial AMR by 10% relative to the 2019 baseline. While modest compared to the scale of the crisis, this target represents the first globally agreed reduction commitment.
• 70% AWaRe Access: At least 70% of human antibiotic use globally should come from the AWaRe “Access” group — first-line antibiotics that are effective, affordable, and less likely to drive resistance. This targets the inappropriate use of broad-spectrum and “Reserve” antibiotics that accelerates resistance.
• 80% diagnostic capacity: At least 80% of countries should be able to test resistance in all GLASS bacterial and fungal pathogens, closing the massive diagnostic gap that currently prevents evidence-based treatment in many settings.
• Universal WASH in healthcare: 100% of countries achieving basic water, sanitation, and hygiene (WASH) services in all healthcare facilities — addressing the infection source rather than just treating resistant infections.
• National IPC programs: 90% of countries meeting WHO minimum requirements for national infection prevention and control (IPC) programs.

These targets reflect a strategic shift from awareness-raising to measurable action. The challenge will be translating political commitment into funded, implemented programs — particularly in the countries most affected by AMR where financing, technical capacity, and health system infrastructure are most constrained.

GLASS Surveillance: Tracking Antimicrobial Resistance Globally

Effective AMR response requires data, and the Global Antimicrobial Resistance and Use Surveillance System (GLASS) is the backbone of global AMR monitoring. The WHO report reveals significant progress in surveillance participation:

• 130 countries enrolled in GLASS as of 2024 — a substantial increase from the system’s launch.
• 104 countries submitted national AMR data — providing the evidence base for tracking resistance trends across pathogens and regions.
• 74 countries submitted antimicrobial use data at least once between 2021 and 2023 — enabling tracking of prescribing patterns that drive resistance.
• National bloodstream infection reporting coverage increased at an average rate of 22.7% per year between 2016 and 2024, reflecting expanding laboratory capacity.

Despite this progress, surveillance gaps remain vast. Many low-income countries lack the laboratory infrastructure to identify resistant organisms reliably, meaning the true burden of AMR in the most affected regions is likely underestimated. GLASS data quality varies significantly between countries, and harmonizing reporting standards across different health systems and laboratory capabilities remains an ongoing challenge. Strengthening diagnostic and surveillance capacity is not just a monitoring exercise — it directly enables better clinical decisions, targeted interventions, and more efficient resource allocation.

WHO’s Four Strategic Priorities for Combating AMR

The WHO report outlines four strategic priorities for the period 2025–2035, providing a comprehensive framework for national and global action:

1. Prevention of Infections

The most cost-effective intervention against AMR is preventing infections in the first place. WHO’s prevention agenda encompasses infection prevention and control (IPC) programs, water, sanitation and hygiene (WASH) infrastructure, pharmaceutical waste management, and vaccination. The report highlights a remarkable finding: vaccines could potentially avert over 10% of deaths associated with AMR while substantially reducing antibiotic consumption. Existing vaccines against pneumococcus, influenza, and other pathogens already reduce infection-driven antibiotic use; expanding vaccine coverage and developing new vaccines targeting resistant pathogens could have transformative impact.

2. Universal Access to Diagnosis and Appropriate Treatment

WHO has established a global AMR diagnostic initiative to strengthen bacteriology and mycology laboratory capacity and services. Beyond diagnostics, this priority encompasses access to new and existing antibiotics, supply chain management to prevent shortages, introduction of novel antibiotics, and antimicrobial stewardship programs guided by the AWaRe classification. The goal is to ensure that every patient receives the right antibiotic, at the right dose, for the right duration — reducing both treatment failure and resistance selection pressure.

3. Strategic Information, Science & Innovation

This priority supports the evidence base through GLASS expansion, improved burden estimates using routine surveillance and modeling, and promotion of prioritized research agendas and product pipelines. The research dimension is critical: the antibiotic development pipeline has been insufficient for decades, with pharmaceutical companies exiting the market due to poor economic returns. Innovative financing mechanisms and public-private partnerships are needed to incentivize development of new antibiotics, diagnostics, and alternative therapies.

4. Effective Governance & Financing

Without governance structures and financing, technical solutions cannot reach the populations that need them. WHO supports countries in implementing national action plans, mainstreaming AMR interventions in primary health care, including AMR in training curricula, and driving awareness through initiatives like World AMR Awareness Week. The report emphasizes the need to integrate AMR into existing health financing mechanisms rather than creating parallel funding streams. For those following global financial systems, the governance challenge of AMR financing illustrates how health security intersects with economic stability.

Prevention: Vaccines, Infection Control & WASH

The prevention pillar deserves particular emphasis because it offers the highest return on investment in the AMR fight. Infection prevention and control (IPC) programs — hand hygiene, environmental cleaning, isolation procedures, antimicrobial stewardship — can reduce healthcare-associated infections by 30–70% in both high- and low-resource settings. When infections don’t occur, antibiotics aren’t needed, and resistance selection pressure is eliminated.

Water, sanitation, and hygiene (WASH) infrastructure is equally fundamental. The WHO target of 100% basic WASH services in all healthcare facilities by 2030 addresses a root cause of infection transmission — particularly in low-income healthcare settings where clean water, functional toilets, and waste management are not guaranteed. Poor WASH infrastructure not only causes infections but contaminates the environment with antibiotics and resistant organisms, creating community-level resistance reservoirs.

The vaccine dimension offers transformative potential. Beyond reducing infections directly, vaccines reduce the demand for antibiotics across entire populations. The WHO estimate that vaccines could avert over 10% of AMR-associated deaths underscores the importance of expanding existing immunization programs and investing in vaccine development targeting key resistant pathogens. This prevention-first approach resonates with the broader public health principle that upstream interventions deliver disproportionate downstream benefits.

Diagnosis and Antimicrobial Stewardship

The AWaRe classification (Access, Watch, Reserve) is WHO’s central tool for promoting appropriate antibiotic use. By categorizing antibiotics based on their clinical importance and resistance potential, AWaRe provides a simple framework for prescribing decisions:

• Access antibiotics: First-line treatments for common infections — effective, affordable, and with lower resistance potential. These should constitute at least 70% of human antibiotic consumption by 2030.
• Watch antibiotics: Broader-spectrum agents with higher resistance potential — recommended only for specific clinical indications.
• Reserve antibiotics: Last-resort treatments for multi-drug resistant infections — their use should be strictly controlled and monitored.

Antimicrobial stewardship programs implement these principles in clinical practice, combining diagnostic testing, prescribing guidelines, prescriber education, and audit-feedback mechanisms to optimize antibiotic use. WHO’s global AMR diagnostic initiative supports this by strengthening the laboratory capacity needed to identify pathogens and their resistance profiles, enabling targeted rather than empiric treatment decisions. The integration of AI and machine learning into diagnostic pathways offers promising avenues for faster, more accurate resistance detection.

The One Health Approach to Antimicrobial Resistance

AMR is not solely a human health problem — it emerges at the intersection of human, animal, and environmental health. The One Health approach, coordinated through the Quadripartite organizations (WHO, FAO, WOAH, and UNEP), recognizes that antibiotic use in livestock, aquaculture, and crop production contributes to resistance selection that ultimately affects human health through food chains, water systems, and environmental contamination.

The Quadripartite Joint Secretariat on AMR coordinates shared work areas including integrated surveillance across sectors, a One Health priority research agenda, the WHO List of Medically Important Antimicrobials (updated 2024), and regulatory strengthening for antimicrobial use in agriculture. The Global Leaders Group on AMR and the AMR Multi-Partner Trust Fund provide governance and financing mechanisms for cross-sectoral coordination.

The environmental dimension — often the least visible pillar of One Health — is increasingly recognized as critical. Pharmaceutical manufacturing waste, agricultural runoff, and wastewater treatment inadequacies release antibiotics and resistant organisms into ecosystems, creating environmental reservoirs of resistance that can transfer back to human pathogens. UNEP’s participation in the Quadripartite reflects growing evidence that environmental interventions are essential to any comprehensive AMR strategy.

National Action Plans: Progress and Significant Gaps

The WHO report reveals a picture of widespread planning but insufficient implementation across member states. The TrACSS (Tracking Antimicrobial Resistance Country Self-Assessment Survey) reached a record 186 countries responding in 2024, with over 170 reporting the existence of national AMR action plans.

However, having a plan and implementing it are very different things:

• 67% of countries report implementing their national action plan — meaning a third have plans that exist largely on paper.
• Only 29% report costing, budgeting, and monitoring implementation — indicating that fewer than one in three countries can measure whether their AMR investments are delivering results.
• Countries consistently report financing, technical capacity, and awareness as the key constraints — particularly in low- and middle-income settings where the AMR burden is highest.

This implementation gap between the existence of national plans and their funded, monitored execution is perhaps the single most important finding in the WHO report. Closing it will require not just additional financing but institutional strengthening, workforce development, and integration of AMR interventions into existing health system workflows. The WHO’s emphasis on mainstreaming AMR into primary health care — rather than creating parallel AMR-specific delivery systems — reflects a pragmatic approach to the financing and capacity constraints that most countries face.

Updating the Global Action Plan on Antimicrobial Resistance

The original global action plan on AMR was adopted by the World Health Assembly in 2015 and subsequently endorsed by FAO, WOAH, and UNEP. The 2024 UN political declaration requests the Quadripartite organizations to update this global action plan by 2026, reflecting a decade of implementation experience and significantly improved understanding of the AMR challenge.

The proposed update process includes:

• Inclusive consultations across member states and stakeholders at regional and global levels
• An initial WHO Member State information session (held March 2025)
• Draft submission to the WHO Executive Board (158th session, January 2026)
• Consideration by the Seventy-ninth World Health Assembly (May 2026)
• Subsequent submission to the governing bodies of FAO, WOAH, and UNEP
• Public feedback opportunity on an outline draft to be published online

The updated plan will need to address the implementation gap head-on — providing not just strategic direction but practical financing mechanisms, implementation support frameworks, and accountability mechanisms that drive measurable progress toward the 2030 targets. For organizations engaged in sustainable development investment, AMR represents an emerging priority where public health, economic development, and environmental sustainability converge.